CompanyGraph
A pharmaceutical distributor that also manufactures medicines, earning most of its revenue from moving drugs between producers and hospitals, pharmacies and other distributors rather than from making them.
- Depends onMidstream position: 6 outgoing, 7 incoming connections
- ScaleRevenue is $42.84B, higher than 95% of all stocks globally
- FinancialsAltman Z-Score 2.11: grey zone
- Interpretations1 currently firing — 1
What this company is and how it runs — written from structure, not news.
The system sits between drug makers, including its own production plants, and the hospitals, pharmacies and distributors that dispense medicine, coordinating the physical movement, storage and delivery of pharmaceutical products between them. A separate part of the business connects international pharmaceutical companies with domestic demand, acting as their route into the local market.
Most revenue comes from one-time product sales recognized when goods change hands, priced for prescription medicines largely through government procurement and bidding rather than open negotiation, and drawn far more from distribution and related services than from manufacturing itself. Nearly all of it is earned domestically, and across the years on record this structure has produced a profit rather than a loss every time.
This system appears to scale less by pushing more volume through a single existing plant or warehouse and more by extending its distribution footprint, adding logistics and production capacity, and absorbing other pharmaceutical and distribution businesses into its network. Its size places it within a large group of other companies that run a broadly similar kind of high-volume distribution business, without indicating where in that group it sits.
Its own filings name specific raw-material and packaging suppliers, describe imported raw materials as exposed to international disruption, and describe its pricing, its new-drug pipeline and its access to specialized talent as dependent on forces it does not control, including government health-insurance policy and regulatory approval. It states it found no material reliance on any single supplier.
A broad range of downstream participants relies on it for access to medicine, including hospitals, retail pharmacies, other distributors, insurers and individual patients, and its own account states that no single customer accounts for a significant share of sales. It also names cooperation agreements with large international drug makers that use its network as a route into the domestic market.
CompanyGraph groups this company, based on how it operates, alongside a large number of other companies that run a similar kind of system in other industries, so that pattern by itself is common rather than rare. The company describes its own position as distinctive because it spans manufacturing, distribution and retail together, and claims a leading national rank in pharmaceutical circulation and in bringing imported drugs to the domestic market, though CompanyGraph cannot see whether other companies could replicate that combination.
CompanyGraph's general expectation for this kind of business is a ceiling set by how much a fixed plant can physically convert, but the company's own account of what limits its growth points elsewhere: the long and uncertain regulatory path for new drugs, government-set pricing through health-insurance procurement, the cost of imported raw materials, and its ability to attract specialized talent. Because most of its revenue comes from distribution and services rather than manufacturing, a physical production ceiling may not be the limit that actually governs it.
The company's own risk disclosures lead with pressures it does not control: international trade conditions affecting imported raw materials, government-set price reductions tied to health-insurance policy, the uncertain road new drugs must travel through regulatory approval, and the risk of writing down goodwill carried from past acquisitions. Separately, CompanyGraph's own pattern reading finds a balance sheet where money owed by customers has grown steadily and makes up a large part of short-term assets, meaning a growing share of recorded revenue sits as uncollected cash rather than cash in hand.
The business operates under direct oversight from national drug-approval and quality regulators as well as securities and health-insurance authorities, and its own disclosures list government-administered pricing through health-insurance procurement as a first-order pressure on what it can charge. It also names international trade conditions and the cost of imported raw materials, plus the long and uncertain path new drugs must travel through regulatory approval, as sources of pressure outside its control.
Read from the company's own filings and public materials (gathered August 2026) together with figures CompanyGraph recomputed from its statements. Written August 2026. A question with no evidence behind it is left out rather than answered.
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.